Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

AstraZeneca blames trial design for Phase 3 failure of bone disease drug

New details from AstraZeneca's failed Phase 3 trial of its enzyme replacement therapy for a genetic bone disease suggest the test missed its goals because of how the trial was composed, as the drugmaker seeks ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Read the original at endpoints.news →

More in Health & Medicine

More from Sunday 11 October →